Evidence map›Paper›PMID 39174797›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature.

Christopher Iriarte, Jennifer E Yeh, Allireza Alloo, Christina Boull, Valerie M Carlberg, Carrie C Coughlin, Irene Lara-Corrales, Rebecca Levy, Cuong V Nguyen, Vikash S Oza and 10 more

Abstract readScoping Review
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Christopher Iriarte *Department of Dermatology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Gryzmish 522, Boston, MA, 02215, USA. ciriarte@bidmc.harvard.edu.
Jennifer E YehDepartment of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA.
Allireza AllooDepartment of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
Christina BoullDepartment of Dermatology, University of Minnesota, Minneapolis, MN, USA.
Valerie M CarlbergDepartment of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA.
Carrie C CoughlinDivision of Dermatology, Departments of Medicine and Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Irene Lara-CorralesDivision of Dermatology, Hospital for Sick Children, Toronto, ON, Canada.
Rebecca LevyDivision of Dermatology, Hospital for Sick Children, Toronto, ON, Canada.
Cuong V NguyenDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Vikash S OzaThe Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA.
Anisha B PatelDepartment of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Veronica RotembergDermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sonal D ShahDepartment of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Lida ZhengDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Corinne H MillerGalter Health Sciences Library and Learning Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Madeline HlobikDermatology Section, Division of Immunology, Boston Children's Hospital, Boston, MA, USA.
Jaclyn DaigneaultDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jennifer N ChoiDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Jennifer T HuangDepartment of Dermatology, Harvard Medical School, Boston, MA, USA.
Karina L VivarDepartment of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMEK inhibitors cause a wide spectrum of mucocutaneous toxicities which can delay or interrupt life-saving therapy. PURPOSE: To summarize the morphology, incidence, and clinical presentation of mucocutaneous toxicities from MEK inhibitors via a scoping review of the literature.

methodsWe conducted a scoping review of the published literature, including clinical trials, retrospective and prospective studies, reviews, and case reports and series. All included literature was analyzed by a panel of pediatric and adult oncodermatologists.

resultsOf 1626 initial citations, 227 articles met final inclusion criteria. Our review identified follicular reactions, ocular toxicities, xerosis, eczematous dermatitis, edema, and paronychia as the most common mucocutaneous side effects from MEK inhibitor therapy. Grade 1 and 2 reactions were the most prevalent and were typically managed while continuing treatment; however, grade 3 toxicities requiring dose reductions or treatment interruptions were also reported.

conclusionMucocutaneous toxicities to MEK inhibitor therapy are common and most often mild in severity. Early recognition and treatment can mitigate disruptions in oncologic therapy.

Indexed as

Protein Kinase InhibitorsAntineoplastic AgentsDrug EruptionsHumansNeoplasmsSeverity of Illness IndexAntineoplastic AgentsProtein Kinase InhibitorsAcneiform eruptionsCutaneous toxicitiesMAPK pathwayMEK inhibitorsSupportive oncodermatologyTargeted therapies

Identifiers

PMID39174797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.